Tissue Collection for Studies of Lymph Cancer
|2||Active, not recruiting||
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
† Study has passed its completion date and status has not been verified in more than two years.